



Medicine: atezolizumab (brand name: Tecentriq®)

Roche Products Ltd

The Scottish Medicines Consortium (SMC) has assessed atezolizumab given on its own for the adjuvant treatment (treatment given after surgery to help stop the cancer coming back) of adult patients with non-small cell lung cancer (NSCLC) that is stage II to IIIA, where the cancer has been successfully removed by surgery. It is used in patients whose tumours have a high level of a protein called PD-L1 (50% or more of the tumour cells have PD-L1) and where the cancer has not got worse after a type of chemotherapy called platinum based chemotherapy, given after surgery. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted atezolizumab for treating adults with NSCLC as described above.

This SMC advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of atezolizumab.

What does SMC's decision mean for patients?

If your healthcare professional thinks that atezolizumab for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.



What is atezolizumab used for?

Atezolizumab is used to help stop the cancer coming back after it has been successfully removed by surgery, in patients with NSCLC that is stage II to IIIA. It is for use in patients whose tumours have a high level of a protein called PD-L1 and where the cancer has not got worse after platinum-based chemotherapy given after the surgery.

How does atezolizumab work?

Atezolizumab is an immunotherapy. This is a type of cancer treatment that stimulates the immune system (the body's natural defence system) to fight the cancer. It works by attaching to a protein called PD-L1. This protein suppresses the body's immune system, preventing cancer cells from being

attacked by the immune cells. By attaching to the protein, atezolizumab helps the immune system to fight the cancer.

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of atezolizumab by looking at the SMC Detailed Advice Document (SMC2492).

More information

The organisations below can provide more information and support for people with lung cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

Roy Castle Lung Cancer Foundation



<https://www.roycastle.org>



0333 323 7200

Scottish Lung Cancer Nurses Forum – affiliated to Lung Cancer Nursing UK



<http://www.lcnuk.org>



01675 477607

You can find out more about atezolizumab (Tecentriq®) in the Patient Leaflet by searching for the medicine name on the electronic medicines compendium (EMC) website.



<https://www.medicines.org.uk/emc/>